Politics
FDA Psychedelics Hearing Focuses On Boosting Therapeutic Innovations While Adhering To Scientific Standards
The Food and Drug Administration (FDA) hosted a hearing on psychedelic therapy on Monday, with the agency and other federal partners that participated taking testimony from dozens of advocates, researchers and industry participants.
Eighty invited witnesses were given two minutes each to briefly summarize their stances and flag issues for federal officials.
Prior to the start of testimony, Marta Sokolowska, deputy director for substance use and behavioral health at FDA’s Center for Drug Evaluation and Research, said that the hearing is “part of a whole of government effort to better understand the opportunities, challenges and public health considerations associated with this evolving area of psychedelic drug treatment.”
“There have been growing interest and active research on the therapeutic potential of psychedelic drugs, in particular for treatment of serious mental health conditions,” she said, noting that as of this weekend, more than 1,800 people had registered for the hearing.
Sokolowska said that FDA has taken “a number of steps to advance psychedelic drug development” in recent years, including publishing guidance for researchers, partnering with other agencies and taking regulatory actions.
Its most recent actions, she said, are intended to support an executive order that President Donald Trump signed earlier this year to streamline research and access into psychedelic medicine.
“This executive order establishes a policy of accelerating innovative research models and appropriate drug approvals to help increase access to psychedelic drugs for serious mental illness,” she said.
“FDA remains committed to supporting innovation while maintaining rigorous scientific and regulatory standards, and for the evaluation of drug safety, effectiveness and quality.”
The FDA official also noted that the agency in April issued national priority vouchers to three companies studying psilocybin for treatment-resistant depression and major depressive disorder, as well as methylone (MDMC) for post-traumatic stress disorder (PTSD), and additionally allowed an early phase clinical study of an ibogaine derivative to proceed with an Investigational New Drug (IND) submission.
Sokolowska also touted a memorandum of understanding that FDA signed with the Department of Veterans Affairs (VA) concerning a partnership to collaborate on research and development of psychedelic medicines to treat people struggling with serious mental health conditions.
Finally, she noted that last week, FDA officials authored a paper in the New England Journal of Medicine that lays out the agency’s “new framework” for psychedelic medicines, including steps they are taking to “make psychedelic therapies available to patients more quickly, as warranted by the nation’s mental health crisis.”
Dayle Cristinzio, director of public engagement at FDA, cautioned that the hearing was “not intended for the promotion of any specific drug or commercial product” and was instead focused on gathering information and perspectives “that may help inform continued work in this area for FDA and our federal partners.”
“Over the course of the afternoon, we heard perspectives addressing provider training and credentialing, promotion of patient safety, considerations for access, best practices for data collection and standardization, as well as a range of related considerations,” she said. “We appreciate the time and the preparation that went into the remarks shared today.”
Cristinzio noted that people can submit comments to an FDA docket about psychedelics through October 5.
Other agencies that participated in Monday’s hearing include the National Institute on Drug Abuse, Substance Abuse and Mental Health Services Administration, Veterans Health Administration and Advanced Research Projects Agency for Health.
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. said in a podcast released last week that he believes there will be an “enormous demand” for psychedelic therapies as they become legally available, and he thinks Trump is unique among his predecessors in championing the issue.
FDA and HHS in April announced steps that they say will help with “accelerating” therapeutic access to psychedelics for patients dealing with serious mental health conditions.
Last month, the Substance Abuse and Mental Health Services Administration issued a report on recent advances in psychedelic medicine, along with recommendations for state policymakers on how to prepare for formal approval of drugs like psilocybin and MDMA. It also noted how the Schedule I status of many psychedelics has hampered scientific studies on their effects for decades.
In May, a bipartisan coalition of 32 members of Congress sent a letter urging FDA to expedite ongoing reviews of psychedelic therapies.
Lawmakers recently filed a new bill that would require the Department of Defense (DOD) to evaluate how ongoing research on the therapeutic benefits of psilocybin could help members of the military.
A separate recently introduced bipartisan measure is intended to codify Trump’s psychedelics executive order into law.
An amendment adopted as part of the National Defense Authorization Act would extend a psychedelics research effort at DOD for an additional six years.
